Belli C, Repetto M, Anand S, et al. The emerging role of PI3K inhibitors for solid tumour treatment and beyond. Br J Cancer. 2023;128(12):2150–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Ding J, Meng LH. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmacol Sin. 2015;36(10):1170–6.

Article  PubMed  PubMed Central  Google Scholar 

U.S. Food & Drug Administration. FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer [media release]. 10 Oct 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive.

Genentech Inc. ITOVEBI (inavolisib) tablets, for oral use: US prescribing information. 2024. https://www.gene.com/download/pdf/itovebi_prescribing.pdf. Accessed 18 Nov 2024.

Genentech. FDA grants Priority Review to Genentech's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation [media release]. 29 May 2024. http://www.gene.com.

Roche. FDA grants Priority Review to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation [media release]. 29 May 2024. http://www.roche.com.

Roche. FDA grants Breakthrough Therapy Designation to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation [media release]. 21 May 2024. http://www.roche.com.

Hanan EJ, Braun MG, Heald RA, et al. Discovery of GDC-0077 (inavolisib), a highly selective inhibitor and degrader of mutant PI3Kα. J Med Chem. 2022;65(24):16589–621.

Article  CAS  PubMed  Google Scholar 

Song KW, Edgar KA, Hanan EJ, et al. RTK-dependent inducible degradation of mutant PI3Kα drives GDC-0077 (inavolisib) efficacy. Cancer Discov. 2022;12(1):204–19.

Article  CAS  PubMed  Google Scholar 

Salphati L, Pang J, Plise EG, et al. Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human. Xenobiotica. 2024. https://doi.org/10.1080/00498254.2024.2415103.

Article  PubMed  Google Scholar 

Marohl T, Tan J, Zhou W, et al. Triple-threat: inavolisib and giredestrant combine with palbociclib to achieve sustained cell cycle arrest in ER-positive breast cancer models [abstract no. 5388]. Cancer Res. 2022;82(12_Suppl.).

Jhaveri KL, Accordino MK, Bedard PL, et al. Phase I/Ib trial of inavolisib plus palbociclib and endocrine therapy for PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer. J Clin Oncol. 2024. https://doi.org/10.1200/JCO.24.00110.

Article  PubMed  Google Scholar 

Cho S, Ma S, Johnson R, et al. Absorption, metabolism, and excretion of inavolisib (GDC-0077), a PI3KA inhibitor in humans [abstract no. P111]. Drug Metab Pharmacokinet. 2024;55(Suppl.):39.

Google Scholar 

Jindal A, Salphati L, Ma S, et al. A single-arm study to investigate absolute bioavailability & mass balance of inavolisib in healthy volunteers using a stable-labeled isotope & a radio-labeled isotope [abstract no. 082]. Clin Pharmacol Drug Dev. 2022;11(S1):92.

Google Scholar 

Turner NC, Im SA, Saura C, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391(17):1584–96.

Article  CAS  PubMed  Google Scholar 

Jhaveri KL, Im S-A, Saura C, et al. Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: phase III INAVO120 primary analysis [presentation]. In: San Antonio Breast Cancer Symposium. 2023.

Juric D, Kalinsky K, Turner NC, et al. First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 phase III randomized trial additional analyses [abstract no. 1003 plus oral presentation]. J Clin Oncol. 2024;42(16_Suppl.).

Rugo H, Gion M, Hernando C, et al. Interim analysis of giredestrant + inavolisib in MORPHEUS Breast Cancer: a phase Ib/II study of giredestrant treatment combinations in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer [abstract no. PS17-07]. Cancer Res. 2024;84(9_Suppl.).

Foundation Medicine. U.S. Food and Drug Administration approves FoundationOne® Liquid CDx as a companion diagnostic for Itovebi™ (inavolisib) to identify patients with hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation [media release]. 11 Oct 2024. http://www.foundationmedicine.com.

Juric D, Kalinsky K, Im S-A, et al. INAVO121: phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC) [abstract no. TPS1136]. J Clin Oncol. 2024;42(16_Suppl.).

Swain SM, Barrios CH, Sr., Basho RK, et al. INAVO122: a phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+aBC) [abstract no. TPS1124]. J Clin Oncol. 2024;42(16_Suppl.).

Roche. Roche Pharma day 2024. 2024. https://assets.roche.com/f/176343/x/f513f69de2/pharma_day_20240930_final_online_v02.pdf. Accessed 18 Nov 2024.

Loibl S, Reinisch M, Denkert C, et al. A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa [abstract no. 200TiP]. Ann Oncol. 2022;33(Suppl. 7):S627.

Article  Google Scholar